2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 388-390
Treatment Considerations, Biological Therapies, Transplantation, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Diseases, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human
PAPER

439 Distinct pathobiology of transplant-associated thrombotic microangiopathy (TA-TMA) in adults versus children: A MIDAS consortium study

Avijeet Kumar Mishra, MD, Lucy Langenberg, MS2, Sheyar Abdullah, BS3, Nathan Luebbering, MS4, Lanie Gardner5, Qiuhong Zhao, MS6, Sonata Jodele, MD7, Anthony Sabulski, MD8, Nelli Bejanyan, MD9, Theresa Hahn, PhD10, Sumithira Vasu, MBBS., MD11, Stella M Davies, MBBS, PhD12
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
5 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
6 The Oho State University, Columbus, United States
7 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
8 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
11 The Oho State University, Columbus, United States
12 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Background: Severe transplant-associated thrombotic microangiopathy (TA-TMA) is a leading cause of non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT), with NRM exceeding 40% in adults. Complement activation is a key driver of TA-TMA, and terminal complement blockade with eculizumab has improved survival from <20% to nearly 70% in pediatric high-risk TA-TMA. However, complement biomarkers (e.g. sC5b-9) do not demonstrate the same diagnostic robustness in adults, and complement blockade has not replicated pediatric success in adult cohorts. The MIDAS (Microangiopathy, Endothelial Damage in Adults undergoing Stem Cell Transplantation) consortium is a prospective, multicenter study of TA-TMA in adult HCT recipients. We hypothesized that the pathobiology of TA-TMA differs between adults and children and performed the first head-to-head comparison of serial biomarkers in adults and children to define age-dependent TA-TMA mechanisms.

Objective: To determine whether TA-TMA pathobiology differs between adults and children by comparing serial inflammatory, endothelial, and complement biomarker trajectories across age groups.

Methods: Serial serum samples were collected at prespecified time points from adult and pediatric HCT recipients. Biomarkers spanning inflammation (CXCL9, CXCL10, suPAR, MCP-1), endothelial injury (ST2), and complement activation (Ba, MASP-2, MBL) were measured. Patients were stratified into severe TA-TMA versus a combined comparator of no TA-TMA and non-severe TA-TMA as non-severe TA-TMA does not alter mortality in either population. Mann-Whitney U and Wilcoxon signed-rank tests compared between-group and longitudinal changes, respectively. Landmark Cox regression evaluated baseline chemokines and severe TA-TMA risk.

Results: Total of 220 adults (median age 60 years, range 21-78) and 125 children (median age 8.9 years, range 0.3-33.5) were included. Median time to TA-TMA was 14.5 days for adults versus 29 days for children. Severe TA-TMA occurred in 18% (40/220) of adults and 28% (35/125) of children. suPAR and MCP-1 were measured in all patients; remaining biomarkers in a randomly selected subset (adults n=113, children n=106).

In adults, inflammatory markers were elevated prior to HCT in severe TA-TMA (suPAR p<0.01 at all time points including pre-HCT; CXCL9 p=0.02 pre-HCT; CXCL10 p=0.02/0.01 at pre-HCT/D7; MCP-1 p<0.01 at D7/D14), suggesting pre-existing inflammation and endothelial activation. On landmark analysis, each doubling of baseline CXCL9 (HR 1.32, 95% CI 1.06–1.63, p=0.013) and CXCL10 (HR 1.43, 95% CI 1.10–1.86, p=0.008) was independently associated with increased hazard of severe TA-TMA in adults but not in children. In children, none differed pre-HCT; suPAR separated only at D28 (p<0.01), and MCP-1/CXCL9/CXCL10 showed no significant separation at any timepoint.

Complement biomarker Ba showed different temporal kinetics: in adults, Ba peaked early (within-patient baseline-to-D14 rise, p=0.007) then declined, with a trend toward higher levels in severe TA-TMA that did not reach statistical significance (p=0.09 at D14). In children, Ba separated between severe and no/non-severe TA-TMA at D28 (p<0.001). MASP-2 did not distinguish severe from no/non-severe TA-TMA in adults (p=0.7, 0.4 at BL/D14) or children (all p>0.5). MBL was similarly non-discriminatory in both cohorts.

ST2 was the sole biomarker behaving similarly across age groups: not elevated at baseline in either cohort, then sharply elevated in severe TA-TMA at D14 and D28 in both adults (p=0.001, p=0.03) and children (p<0.001, p<0.001). Within-patient ST2 rose significantly from baseline to D14 and D28 (p<0.0001) in both populations.

Conclusions: TA-TMA exhibits age-dependent pathobiology. Adults develop TA-TMA on a background of pre-existing inflammation and endothelial injury with early, transient complement activation, while children develop acute complement-mediated injury to a previously intact endothelium. MASP-2 does not identify severe TA-TMA in either population. ST2 is a strong age-independent biomarker, likely reflecting the consequences rather than the etiology of endothelial injury. These findings support age-adapted biomarker and therapeutic strategies for TA-TMA. In particular, the pre-HCT inflammatory signature in adults, marked by elevated CXCL9/CXCL10, identifies a potentially targetable upstream pathway that warrants investigation as a preventive or adjunctive strategy in adult TA-TMA.

Avijeet Kumar Mishra, MD: No relevant conflicts of interest to declare.